Daxor Announces Virginia Commonwealth University Medical Center of Richmond, VA Acquires Blood Volume Analyzer BVA-100

Market Wire, October, 2007

Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed clinical trial agreement for a Blood Volume Analyzer BVA-100 from Virginia Commonwealth University Medical Center of Richmond, Virginia.

Virginia Commonwealth University (VCU) Medical Center is a fully accredited Level I trauma center and teaching medical center serving Central Virginia. VCU Medical Center is ranked as one of the nation's Best Hospitals in 2007 by U.S. News & World Report and has also been recognized by The American Nurses Credentialing Center, which awarded Virginia Commonwealth University Health System Magnet status, the highest honor and level of recognition the group awards to nursing excellence in national and international health care. VCU Medical Center is fully accredited in cardiac and aortic surgical procedures and is recognized as offering the region's most honored open-heart surgery program. VCU Medical Center is also one of the nations leading institutions in the field of blood conservation.

The national average for transfusion of blood in cardiac surgical patients has been reported in various published clinical studies to be as high as 60%. At VCU, the transfusion rate is less than 20%. Transfusion of blood for heart surgery accounts for about 20% of all the blood used in the United Sates and up to 34% in parts of Europe. The latest data are sobering showing that patients who receive more blood transfusions have worse outcomes, more heart attacks, more heart failure, longer times in the hospital, longer times on ventilators, more infections and twice the death rate, even out to five years after heart surgery. Daxor's BVA-100 will be used in cardiac surgery patients to measure their blood volume status prior to and post cardiac surgery.

Dr. Mark Nelson, the study's principle investigator noted, "Transfusion of blood is not as benign as was once assumed. This technology will allow us to examine the patient's true blood volume and, along with other information, determine in which patients' transfusion is truly necessary. We expect the data we collect to profoundly impact the current national transfusion practices in cardiac surgical patients." Following the installation of the BVA-100 physicians will begin collecting data on blood volumes in cardiac surgical patients and hope to publish their preliminary findings later this year.

Daxor Corporation manufactures and markets the BVA-100, the only FDA-approved semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com .

Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Email Contact or Diane Meegan Investor Relations 212-330-8512 Email Contact